Angiotensin-converting enzyme inhibitors and angiotensin II type I receptor blockers after renal transplantation

被引：10

作者：

Morath, C. ^{[1
]}

Schmied, B. ^{[2
]}

Mehrabi, A. ^{[2
]}

Weitz, J. ^{[2
]}

Schmidt, J. ^{[2
]}

Werner, J. ^{[2
]}

Buchler, M. W. ^{[2
]}

Morcos, M. ^{[3
]}

Nawroth, P. P. ^{[3
]}

Schwenger, V. ^{[1
]}

Doehler, B. ^{[4
]}

Opelz, G. ^{[4
]}

Zeier, M. ^{[1
]}

机构：

[1] Univ Heidelberg, Dept Nephrol, D-69120 Heidelberg, Germany

[2] Univ Heidelberg, Dept Gen Surg, D-69120 Heidelberg, Germany

[3] Univ Heidelberg, Dept Endocrinol, D-69120 Heidelberg, Germany

[4] Univ Heidelberg, Dept Transplantat Immunol, D-69120 Heidelberg, Germany

来源：

CLINICAL TRANSPLANTATION | 2009年 / 23卷

关键词：

Angiotensin-converting enzyme inhibitor; angiotension II type 1 receptor blocker; renal transplantation; chronic allograft dysfunction; CHRONIC ALLOGRAFT NEPHROPATHY; KIDNEY-TRANSPLANTATION; PLASMA-LEVELS; SYSTEM BLOCKADE; GRAFT-SURVIVAL; RECIPIENTS; LOSARTAN; PATIENT; TRIAL; IMPROVEMENT;

D O I：

10.1111/j.1399-0012.2009.01107.x

中图分类号：

R61 [外科手术学];

学科分类号：

摘要：

Renin-angiotensin system blockade retards the progression of diabetic and non-diabetic chronic kidney disease of the native kidneys. Though most patients suffer from a significant renal insufficiency (Chronic kidney disease stage III) and a concomitant heart disease after renal transplantation, there is Up to now no evidence supporting the use of inhibitors of the renin-angiotensin system in these patients. We wish to summarize the available evidence on the use of inhibitors of the renin-angiotensin system after renal transplantation. We specifically discuss potential beneficial as well as adverse effects of a renin-angiotensin system blockade. In addition, we review their influence on morphologic and biochemical markers as well as on renal function, graft and patient survival after renal transplantation.

引用

页码：33 / 36

页数：4

共 23 条

[1] Losartan decreases plasma levels of TGF-β1 in transplant patients with chronic allograft nephropathy [J].

Campistol, JM ;

Iñigo, P ;

Jimenez, W ;

Lario, S ;

Clesca, PH ;

Oppenheimer, F ;

Rivera, F .

KIDNEY INTERNATIONAL, 1999, 56 (02) :714-719

[2] The renin angiotensin system blockade in kidney transplantation:: pros and cons [J].

Cruzado, Josep M. ;

Rico, Jorge ;

Grinyo, Josep M. .

TRANSPLANT INTERNATIONAL, 2008, 21 (04) :304-313

[3] Effect of angiotensin II receptor blocker on plasma levels of TGF-β1 and interstitial fibrosis in hypertensive kidney transplant patients [J].

El-Agroudy, AE ;

Hassan, NA ;

Foda, MA ;

Ismail, AM ;

El-Sawy, EA ;

Mousa, O ;

Ghoneim, MA .

AMERICAN JOURNAL OF NEPHROLOGY, 2003, 23 (05) :300-306

[4] Potential advantages and limitations of applying the chronic kidney disease classification to kidney transplant recipients [J].

Gill, J. S. .

AMERICAN JOURNAL OF TRANSPLANTATION, 2006, 6 (12) :2821-2826

[5] Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation [J].

Heinze, Georg ;

Mitterbauer, Christa ;

Regele, Heinz ;

Kramar, Reinhard ;

Winkelmayer, Wolfgang C. ;

Curhan, Gary C. ;

Oberbauer, Rainer .

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2006, 17 (03) :889-899

[6] Prediction of left ventricular mass changes after renal transplantation by polymorphism of the angiotensin-converting-enzyme gene [J].

Hernandez, D ;

Lacalzada, J ;

Rufino, M ;

Torres, A ;

Martin, N ;

Barragan, A ;

Barrios, Y ;

Macia, M ;

DeBonis, E ;

Lorenzo, V ;

Rodriguez, A ;

GonzalezPosada, JM ;

Salido, E .

KIDNEY INTERNATIONAL, 1997, 51 (04) :1205-1211

[7] Renin angiotensin system blockade in kidney transplantation: A systematic review of the evidence [J].

Hiremath, S. ;

Fergusson, D. ;

Doucette, S. ;

Mulay, A. V. ;

Knoll, G. A. .

AMERICAN JOURNAL OF TRANSPLANTATION, 2007, 7 (10) :2350-2360

[8]

Iñigo P, 2001, J AM SOC NEPHROL, V12, P822, DOI 10.1681/ASN.V124822

[9] The Canadian ACE-inhibitor trial to improve renal outcomes and patient survival in kidney transplantation - study design [J].

Knoll, Greg A. ;

Cantarovitch, Marcelo ;

Cole, Ed ;

Gill, John ;

Gourishankar, Sita ;

Holland, Dave ;

Kiberd, Bryce ;

Muirhead, Norman ;

Prasad, Ramesh ;

Tibbles, Lee Anne ;

Treleaven, Darin ;

Fergusson, Dean .

NEPHROLOGY DIALYSIS TRANSPLANTATION, 2008, 23 (01) :354-358

[10] Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes [J].

Lewis, EJ ;

Hunsicker, LG ;

Clarke, WR ;

Berl, T ;

Pohl, MA ;

Lewis, JB ;

Ritz, E ;

Atkins, RC ;

Rohde, R ;

Raz, I .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :851-860

← 1 2 3 →